Authentification abonné
lvrea
Accueil Tous les numéros Volume 27 / Numéro 4 (Juillet 2018) Méd. Intensive Réa., 27 4 (2018) 344-366 Références
Accès gratuit
Numéro
Méd. Intensive Réa.
Volume 27, Numéro 4, Juillet 2018
Médecine interne et transversalité
Page(s) 344 - 366
Section Mise au point / Update
DOI https://doi.org/10.3166/rea-2018-0056
Publié en ligne 29 août 2018
  • Harpaz R, Dahl RM, Dooling KL, (2016) Prevalence of immunosuppression among US Adults, 2013. JAMA 316: 2547–2548. doi: 10.1001/jama.2016.16477 [CrossRef] [PubMed] [Google Scholar]
  • Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK, (2017) Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst 109. doi: 10.1093/jnci/djx030 [Google Scholar]
  • Canet E, Zafrani L, Azoulay E, (2016) The critically ill kidney transplant recipient: a narrative review. Chest 149: 1546–1555. doi: 10.1016/j.chest.2016.01.002 [CrossRef] [PubMed] [Google Scholar]
  • Dumas G, Géri G, Montlahuc C, Chemam S, Dangers L, Pichereau C, Brechot N, Duprey M, Mayaux J, Schenck M, Boisramé-Helms J, Thomas G, Baboi L, Mouthon L, Amoura Z, Papo T, Mahr A, Chevret S, Chiche JD, Azoulay E, (2015) Outcomes in critically ill patients with systemic rheumatic disease: a multicenter study. Chest 148: 927–935. doi: 10.1378/chest.14-3098 [CrossRef] [PubMed] [Google Scholar]
  • Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J, Vincent F, Nyunga M, Bruneel F, Laisne LM, Rabbat A, Lebert C, Perez P, Chaize M, Renault A, Meert AP, Benoit D, Hamidfar R, Jourdain M, Darmon M, Schlemmer B, Chevret S, Lemiale V, (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium: a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol 31: 2810–2818. doi: 10.1200/JCO.2012.47.2365 [CrossRef] [PubMed] [Google Scholar]
  • Azoulay E, Pickkers P, Soares M, Perner A, Rello J, Bauer PR, van de Louw A, Hemelaar P, Lemiale V, Taccone FS, Martin Loeches I, Meyhoff TS, Salluh J, Schellongowski P, Rusinova K, Terzi N, Mehta S, Antonelli M, Kouatchet A, Barratt-Due A, Valkonen M, Landburg PP, Bruneel F, Bukan RB, Pène F, Metaxa V, Moreau AS, Souppart V, Burghi G, Girault C, Silva UVA, Montini L, Barbier F, Nielsen LB, Gaborit B, Mokart D, Chevret S, Efraim investigators and the Nine-I study group, (2017) Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med 43: 1808–1819. doi: 10.1007/s00134-017-4947-1 [CrossRef] [PubMed] [Google Scholar]
  • Contejean A, Lemiale V, Resche-Rigon M, Mokart D, Pène F, Kouatchet A, Mayaux J, Vincent F, Nyunga M, Bruneel F, Rabbat A, Perez P, Meert AP, Benoit D, Hamidfar R, Darmon M, Jourdain M, Renault A, Schlemmer B, Azoulay E, (2016) Increased mortality in hematological malignancy patients with acute respiratory failure from undetermined etiology: a Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologique (Grrr-OH) study. Ann Intensive Care 6: 102. doi: 10.1186/s13613-016-0202-0 [CrossRef] [PubMed] [Google Scholar]
  • Schnell D, Mayaux J, Lambert J, Roux A, Moreau AS, Zafrani L, Canet E, Lemiale V, Darmon M, Azoulay E, (2013) Clinical assessment for identifying causes of acute respiratory failure in cancer patients. Eur Respir J 42: 435–443. doi: 10.1183/09031936.00122512 [CrossRef] [PubMed] [Google Scholar]
  • Novosad SA, Winthrop KL, (2014) Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis 58: 1587–1598. doi: 10.1093/cid/ciu104 [CrossRef] [PubMed] [Google Scholar]
  • Salvana EMT, Salata RA, (2009) Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 22: 274–290, Table of Contents. doi: 10.1128/CMR.00040-08 [CrossRef] [PubMed] [Google Scholar]
  • Janeway CA Jr, Travers P, Walport M, Shlomchik MJ, (2001) Immunobiology, 5th ed. Garland Science [Google Scholar]
  • Morrison VA, (2014) Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis 59: S360–S364. doi: 10.1093/cid/ciu592 [CrossRef] [PubMed] [Google Scholar]
  • Carroll MC, Holers VM, (2005) Innate autoimmunity. Adv Immunol 86: 137–157. doi: 10.1016/S0065-2776(04)86004-8 [CrossRef] [PubMed] [Google Scholar]
  • Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Holland SM, Klein C, Nonoyama S, Ochs HD, Oksenhendler E, Puck JM, Sullivan KE, Tang ML, Franco JL, Gaspar HB, (2015) Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol 35: 696–726. doi: 10.1007/s10875-015-0201-1 [CrossRef] [PubMed] [Google Scholar]
  • Medzhitov R, (2007) Recognition of microorganisms and activation of the immune response. Nature 449: 819–826. doi: 10.1038/nature06246 [CrossRef] [PubMed] [Google Scholar]
  • Fleer A, (2000) Cellular and humoral defence mechanisms against bacteria. Paediatr Respir Rev 1: 235–240. doi: 10.1053/prrv.2000.0054 [PubMed] [Google Scholar]
  • Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, Vlkova M, Hernandez M, Detkova D, Bos PR, Poerksen G, von Bernuth H, Baumann U, Goldacker S, Gutenberger S, Schlesier M, Bergeron-van der Cruyssen F, Le Garff M, Debré P, Jacobs R, Jones J, Bateman E, Litzman J, van Hagen PM, Plebani A, Schmidt RE, Thon V, Quinti I, Espanol T, Webster AD, Chapel H, Vihinen M, Oksenhendler E, Peter HH, Warnatz K, (2008) The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 111: 77–85. doi: 10.1182/blood-2007-06-091744 [CrossRef] [Google Scholar]
  • Azar AE, Ballas ZK, (2007) Evaluation of the adult with suspected immunodeficiency. Am J Med 120: 764–768. doi: 10.1016/j.amjmed.2006.12.013 [CrossRef] [Google Scholar]
  • Casulo C, Maragulia J, Zelenetz AD, (2013) Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 13: 106–111. doi: 10.1016/j.clml.2012.11.011 [CrossRef] [PubMed] [Google Scholar]
  • Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loët X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X; AutoImmunity and Rituximab registry and French Society of Rheumatology, (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62: 2625–2632. doi: 10.1002/art.27555 [CrossRef] [PubMed] [Google Scholar]
  • Arai Y, Yamashita K, Mizugishi K, Kondo T, Kitano T, Hishizawa M, Kadowaki N, Takaori-Kondo A, (2014) Risk factors for hypogammaglobulinemia after allo-SCT. Bone Marrow Transplant 49: 859–861. doi: 10.1038/bmt.2014.28 [CrossRef] [PubMed] [Google Scholar]
  • Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, Viallard JF, Gardembas M, Galicier L, Schleinitz N, Suarez F, Soulas-Sprauel P, Hachulla E, Jaccard A, Gardeur A, Théodorou I, Rabian C, Debré P; DEFI Study Group, (2008) Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 46: 1547–1554. doi: 10.1086/587669 [CrossRef] [PubMed] [Google Scholar]
  • Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD, (2017) European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 50. pii: 1700629. doi: 10.1183/13993003.00629-2017 [CrossRef] [PubMed] [Google Scholar]
  • Tarr PE, Sneller MC, Mechanic LJ, Economides A, Eger CM, Strober W, Cunningham-Rundles C, Lucey DR, (2001) Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature. Medicine (Baltimore) 80: 123–133 [CrossRef] [PubMed] [Google Scholar]
  • Compagno N, Malipiero G, Cinetto F, Agostini C, (2014) Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia. Front Immunol 5: 626. doi: 10.3389/fimmu.2014.00626 [CrossRef] [PubMed] [Google Scholar]
  • Ricklin D, Hajishengallis G, Yang K, Lambris JD, (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785–797. doi: 10.1038/ni.1923 [CrossRef] [PubMed] [Google Scholar]
  • Turley AJ, Gathmann B, Bangs C, Bradbury M, Seneviratne S, Gonzalez-Granado LI, Hackett S, Kutukculer N, Alachkar H, Hambleton S, Ritterbusch H, Kralickova P, Marodi L, Seidel MG, Dueckers G, Roesler J, Huissoon A, Baxendale H, Litzman J, Arkwright PD, (2015) Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J Clin Immunol 35: 199–205. doi: 10.1007/s10875-015-0137-5 [CrossRef] [PubMed] [Google Scholar]
  • Audemard-Verger A, Descloux E, Ponard D, Deroux A, Fantin B, Fieschi C, John M, Bouldouyre A, Karkowsi L, Moulis G, Auvinet H, Valla F, Lechiche C, Davido B, Martinot M, Biron C, Lucht F, Asseray N, Froissart A, Buzelé R, Perlat A, Boutboul D, Fremeaux-Bacchi V, Isnard S, Bienvenu B, (2016) Infections revealing complement deficiency in adults. Medicine (Baltimore) 95: e3548. doi: 10.1097/MD.0000000000003548 [CrossRef] [PubMed] [Google Scholar]
  • Benamu E, Montoya JG, (2016) Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 29: 319–329. doi: 10.1097/QCO.0000000000000279 [CrossRef] [PubMed] [Google Scholar]
  • Di Sabatino A, Carsetti R, Corazza GR, (2011) Post-splenectomy and hyposplenic states. Lancet Lond Engl 378: 86–97. doi: 10.1016/S0140-6736(10)61493-6 [CrossRef] [Google Scholar]
  • Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, Plebani A, Kumararatne DS, Bonnet D, Tournilhac O, Tchernia G, Steiniger B, Staudt LM, Casanova JL, Reynaud CA, Weill JC, (2004) Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104: 3647–3654. doi: 10.1182/blood-2004-01-0346 [CrossRef] [PubMed] [Google Scholar]
  • O’Neal HR, Niven AS, Karam GH, (2016) Critical Illness in Patients With Asplenia. Chest 150: 1394–1402. doi: 10.1016/j.chest.2016.03.044 [CrossRef] [PubMed] [Google Scholar]
  • Robinette CD, Fraumeni JF, (1977) Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet Lond Engl 2: 127–129 [CrossRef] [Google Scholar]
  • Fair KA, Connelly CR, Hart KD, Schreiber MA, Watters JM, (2017) Splenectomy is associated with higher infection and pneumonia rates among trauma laparotomy patients. Am J Surg 213: 856–861. doi: 10.1016/j.amjsurg.2017.04.001 [CrossRef] [PubMed] [Google Scholar]
  • Theilacker C, Ludewig K, Serr A, Schimpf J, Held J, Bögelein M, Bahr V, Rusch S, Pohl A, Kogelmann K, Frieseke S, Bogdanski R, Brunkhorst FM, Kern WV, (2016) Overwhelming Postsplenectomy Infection: A Prospective Multicenter Cohort Study. Clin Infect Dis 62: 871–878. doi: 10.1093/cid/civ1195 [CrossRef] [PubMed] [Google Scholar]
  • Bhavsar AP, Guttman JA, Finlay BB, (2007) Manipulation of host-cell pathways by bacterial pathogens. Nature 449: 827–834. doi: 10.1038/nature06247 [CrossRef] [PubMed] [Google Scholar]
  • Weiss G, Schaible UE, (2015) Macrophage defense mechanisms against intracellular bacteria. Immunol Rev 264: 182–203. doi: 10.1111/imr.12266 [CrossRef] [PubMed] [Google Scholar]
  • Berliner N, Horwitz M, Loughran TP, (2004) Congenital and acquired neutropenia. Hematol Am Soc Hematol Educ Program 2004: 63–79. doi: 10.1182/asheducation-2004.1.63 [Google Scholar]
  • de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F; ESMO Guidelines Working Group, (2010) Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 21: v252–v256. doi: 10.1093/annonc/mdq196 [CrossRef] [PubMed] [Google Scholar]
  • Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America, (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52: e56–e93. doi: 10.1093/cid/cir073 [CrossRef] [PubMed] [Google Scholar]
  • Evans SE, Ost DE, (2015) Pneumonia in the neutropenic cancer patient. Curr Opin Pulm Med 21:260–271. doi: 10.1097/MCP.0000000000000156 [CrossRef] [PubMed] [Google Scholar]
  • Vento S, Cainelli F, Temesgen Z, (2008) Lung infections after cancer chemotherapy. Lancet Oncol 9:982–992. doi: 10.1016/S1470-2045(08)70255-9 [CrossRef] [PubMed] [Google Scholar]
  • Subirà M, Martino R, Franquet T, Puzo C, Altés A, Sureda A, Brunet S, Sierra J, (2002) Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica 87: 528–534 [PubMed] [Google Scholar]
  • Cornely OA, Arikan‐Akdagli S, Dannaoui E, Groll AH. Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca‐Estrella M, Freiberger T, Guinea J, Guarro J, de Hoog S, Hope W, Johnson E, Kathuria S, Lackner M, Lass‐Flörl C, Lortholary O, Meis JF, Meletiadis J, Muñoz P, Richardson M, Roilides E, Tortorano AM, Ullmann AJ, van Diepeningen A, Verweij P, Petrikkos G, (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 20: 5–26. doi: 10.1111/1469-0691.12371 [CrossRef] [Google Scholar]
  • Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE, (2016) Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 63: 433–442. doi: 10.1093/cid/ciw444 [CrossRef] [PubMed] [Google Scholar]
  • Wingard JR, Hiemenz JW, Jantz MA, (2012) How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation. Blood 120: 1791–1800. doi: 10.1182/blood-2012-02-378976 [CrossRef] [Google Scholar]
  • Milito MA, Kontoyiannis DP, Lewis RE, Liu P, Mawlawi OR, Truong MT, Marom EM, (2010) Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis. Med Mycol 48: 817–823. doi: 10.3109/13693780903514872 [CrossRef] [Google Scholar]
  • Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, Troke PF, Denning DW, Bennett JE, de Pauw BE, Rubin RH, (2007) Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44: 373–379. doi: 10.1086/509917 [CrossRef] [PubMed] [Google Scholar]
  • Bergeron A, Porcher R, Sulahian A, de Bazelaire C, Chagnon K, Raffoux E, Vekhoff A, Cornet M, Isnard F, Brethon B, Lacroix C, Poirot JL, Bouges C, Derouin F, Tazi A, Ribaud P, (2012) The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood 119: 1831–1837; quiz 1956. doi: 10.1182/blood-2011-04-351601 [CrossRef] [Google Scholar]
  • Rolston KVI, Bodey GP, Safdar A, (2007) Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis Off Publ Infect Dis Soc Am 45:228–233. doi: 10.1086/518873 [CrossRef] [Google Scholar]
  • Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP, (2005) Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41: 60–66. doi: 10.1086/430710 [CrossRef] [PubMed] [Google Scholar]
  • Reichenberger F, Habicht JM, Gratwohl A, Tamm M, (2002) Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 19: 743–755 [CrossRef] [PubMed] [Google Scholar]
  • Nucci M, Anaissie E, (2007) Fusarium infections in immunocompromised patients. Clin Microbiol Rev 20: 695–704. doi: 10.1128/CMR.00014-07 [CrossRef] [PubMed] [Google Scholar]
  • Lekstrom-Himes JA, Gallin JI, (2000) Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 343: 1703–1714. doi: 10.1056/NEJM200012073432307 [CrossRef] [PubMed] [Google Scholar]
  • Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B, (2017) Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129: 553–560. doi: 10.1182/blood-2016-01-689422 [CrossRef] [Google Scholar]
  • Ahmed S, Siddiqui AK, Rossoff L, Sison CP, Rai KR, (2003) Pulmonary complications in chronic lymphocytic leukemia. Cancer 98: 1912–1917. doi: 10.1002/cncr.11736 [CrossRef] [PubMed] [Google Scholar]
  • Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ, Center for International Blood and Marrow Research, National Marrow Donor program, European Blood and MarrowTransplant Group, American Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Disease Canada, Centers for Disease Control and Prevention, (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15: 1143–1238. doi: 10.1016/j.bbmt.2009.06.019 [CrossRef] [PubMed] [Google Scholar]
  • Dettenkofer M, Wenzler-Röttele S, Babikir R, Bertz H, Ebner W, Meyer E, Rüden H, Gastmeier P, Daschner FD, Hospital Infection Surveillance System for Patients with Hematologic/Oncologic Malignancies Study Group, (2005) Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project. Clin Infect Dis 40: 926–931. doi: 10.1086/428046 [CrossRef] [PubMed] [Google Scholar]
  • Gil L, Kozlowska-Skrzypczak M, Mol A, Poplawski D, Styczynski J, Komarnicki M, (2009) Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant 43: 121–126. doi: 10.1038/bmt.2008.303 [CrossRef] [PubMed] [Google Scholar]
  • Miller HK, Braun TM, Stillwell T, Harris AC, Choi S, Connelly J, Couriel D, Goldstein S, Kitko CL, Magenau J, Pawarode A, Reddy P, Riwes M, Yanik GA, Levine JE, (2017) Infectious risk after allogeneic hematopoietic cell transplantation complicated by acute graft-versus-host disease. Biol Blood Marrow Transplant 23: 522–528. doi: 10.1016/j.bbmt.2016.12.630 [CrossRef] [PubMed] [Google Scholar]
  • Matsumura-Kimoto Y, Inamoto Y, Tajima K, Kawajiri A, Tanaka T, Hirakawa T, Ino K, Asao Y, Tamogami H, Kono C, Takeda W, Okinaka K, Fuji S, Kurosawa S, Kim SW, Tanosaki R, Yamashita T, Fukuda T, (2016) Association of cumulative steroid dose with risk of infection after treatment for severe acute graft-versus-host disease. Biol Blood Marrow Transplant 22: 1102–1107. doi: 10.1016/j.bbmt.2016.02.020 [CrossRef] [PubMed] [Google Scholar]
  • Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, Potter M, Peggs K, Clark A; British Committee for Standards in Haematology, British Society of Blood and Marrow Transplantation, UK Virology Network, (2013) Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol 162: 25–39. doi: 10.1111/bjh.12363 [CrossRef] [PubMed] [Google Scholar]
  • Williams KM, Ahn KW, Chen M, Aljurf MD, Agwu AL, Chen AR, Walsh TJ, Szabolcs P, Boeckh MJ, Auletta JJ, Lindemans CA, Zanis-Neto J, Malvezzi M, Lister J, de Toledo Codina JS, Sackey K, Chakrabarty JL, Ljungman P, Wingard JR, Seftel MD, Seo S, Hale GA, Wirk B, Smith MS, Savani BN, Lazarus HM, Marks DI, Ustun C, Abdel-Azim H, Dvorak CC, Szer J, Storek J, Yong A, Riches MR, (2016) The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant 51: 573–580. doi: 10.1038/bmt.2015.316 [CrossRef] [PubMed] [Google Scholar]
  • Erard V, Guthrie KA, Seo S, Smith J, Huang M, Chien J, Flowers ME, Corey L, Boeckh M, (2015) Reduced mortality of cytomegalovirus Pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis Off Publ Infect Dis Soc Am 61: 31–39. doi: 10.1093/cid/civ215 [CrossRef] [Google Scholar]
  • Travi G, Pergam SA, (2014) Cytomegalovirus pneumonia in hematopoietic stem cell recipients. J Intensive Care Med 29: 200–212. doi: 10.1177/0885066613476454 [CrossRef] [PubMed] [Google Scholar]
  • Kotton CN, (2013) CMV: Prevention, Diagnosis and Therapy. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 13: 24–40; quiz 40. doi: 10.1111/ajt.12006 [CrossRef] [Google Scholar]
  • Girmenia C, Ferretti A, Barberi W, (2014) Epidemiology and risk factors for invasive fungal diseases in hematopoietic stem cell transplantation. Curr Opin Hematol 21: 459–465. doi: 10.1097/MOH.0000000000000086 [CrossRef] [PubMed] [Google Scholar]
  • Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S, (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356: 335–347. doi: 10.1056/NEJMoa061098 [CrossRef] [PubMed] [Google Scholar]
  • de la Cámara R, Martino R, Granados E, Rodriguez-Salvanés FJ, Rovira M, Cabrera R, López J, Parody R, Sierra J, Fernández-Rañada JM, Carreras E, (2000) Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. Spanish Group on Infectious Complications in Hematopoietic Transplantation. Bone Marrow Transplant 26: 291–298. doi: 10.1038/sj.bmt.1702506 [CrossRef] [PubMed] [Google Scholar]
  • Cordonnier C, Martino R, Trabasso P, Held TK, Akan H, Ward MS, Fabian K, Ullmann AJ, Wulffraat N, Ljungman P, Alessandrino EP, Pretnar J, Gmür J, Varela R, Vitek A, Sica S, Rovira M, European Blood and Marrow Transplant Group Infectious Diseases Working Party, (2004) Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis 38: 1229–1236. doi: 10.1086/383307 [CrossRef] [PubMed] [Google Scholar]
  • Giannella M, Muñoz P, Alarcón JM, Mularoni A, Grossi P, Bouza E, PISOT study group, (2014) Pneumonia in solid organ transplant recipients: a prospective multicenter study. Transpl Infect Dis 16: 232–241. doi: 10.1111/tid.12193 [CrossRef] [PubMed] [Google Scholar]
  • Villacian JS, Paya CV, (1999) Prevention of infections in solid organ transplant recipients. Transpl Infect Dis 1: 50–64 [CrossRef] [PubMed] [Google Scholar]
  • Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U, (2013) What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant 13: 2601–2610. doi: 10.1111/ajt.12401 [CrossRef] [PubMed] [Google Scholar]
  • Zafrani L, Truffaut L, Kreis H, Etienne D, Rafat C, Lechaton S, Anglicheau D, Zuber J, Ciroldi M, Thervet E, Snanoudj R, Mamzer MF, Martinez F, Timsit MO, Bergougnoux L, Legendre C, (2009) Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transplant 9: 1816–1825. doi: 10.1111/j.1600-6143.2009.02699.x [CrossRef] [PubMed] [Google Scholar]
  • Fishman JA, (2007) Infection in solid-organ transplant recipients. N Engl J Med 357:2601–2614. doi: 10.1056/NEJMra064928 [CrossRef] [PubMed] [Google Scholar]
  • Kovats Z, Sütto Z, Muraközy G, Bohacs A, Czebe K, Lang G, Renyi-Vamos F, Klepetko W, Müller V, (2011) Airway pathogens during the first year after lung transplantation: a single-center experience. Transplant Proc 43: 1290–1291. doi: 10.1016/j.transproceed.2011.03.075 [CrossRef] [PubMed] [Google Scholar]
  • Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM, (2010) Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50: 1101–1111. doi: 10.1086/651262 [CrossRef] [PubMed] [Google Scholar]
  • Gavalda J, Len O, San Juan R, Aguado JM, Fortun J, Lumbreras C, Moreno A, Munoz P, Blanes M, Ramos A, Rufi G, Gurgui M, Torre-Cisneros J, Montejo M, Cuenca-Estrella M, Rodriguez-Tudela JL, Pahissa A, RESITRA (Spanish Network for Research on Infection in Transplantation), (2005) Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 41: 52–59. doi: 10.1086/430602 [CrossRef] [PubMed] [Google Scholar]
  • Fishman JA, (2017) Infection in Organ Transplantation. Am J Transplant 17: 856–879. doi: 10.1111/ajt.14208 [CrossRef] [Google Scholar]
  • Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, Fresnel A, Guiguen C, Le Tulzo Y, Jégo P, Tattevin P, (2014) Incidence of Pneumocystis jiroveci Pneumonia among Groups at Risk in HIV-negative Patients. Am J Med 127: 1242.e11–1242.e17. doi: 10.1016/j.amjmed.2014.07.010 [CrossRef] [Google Scholar]
  • Bige N, Zafrani L, Lambert J, Peraldi MN, Snanoudj R, Reuter D, Legendre C, Chevret S, Lemiale V, Schlemmer B, Azoulay E, Canet E, (2014) Severe infections requiring intensive care unit admission in kidney transplant recipients: impact on graft outcome. Transpl Infect Dis 16: 588–596. doi: 10.1111/tid.12249 [CrossRef] [PubMed] [Google Scholar]
  • Gavaldà J, Meije Y, Fortún J, Roilides E, Saliba F, Lortholary O, Muñoz P, Grossi P, Cuenca-Estrella M, ESCMID Study Group for Infections in Compromised Hosts, (2014) Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect 20: 27–48. doi: 10.1111/1469-0691.12660 [CrossRef] [Google Scholar]
  • Grossi P, Farina C, Fiocchi R, Dalla Gasperina D, (2000) Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 70: 112–116 [PubMed] [Google Scholar]
  • Singh N, Aguado JM, Bonatti H, Forrest G, Gupta KL, Safdar N, John GT, Pursell KJ, Muñoz P, Patel R, Fortun J, Martin-Davila P, Philippe B, Philit F, Tabah A, Terzi N, Chatelet V, Kusne S, Clark N, Blumberg E, Julia MB, Humar A, Houston S, Lass-Flörl C, Johnson L, Dubberke ER, Barron MA, Lortholary O, (2009) Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 200: 1002–1011. doi: 10.1086/605445 [CrossRef] [PubMed] [Google Scholar]
  • Miller R, Assi M, AST Infectious Diseases Community of Practice, (2013) Endemic fungal infections in solid organ transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 13 Suppl 4: 250–261. doi: 10.1111/ajt.12117 [CrossRef] [Google Scholar]
  • Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, Cervera C, Len O, Carratala J, Cisneros JM, Bou G, Muñoz P, Ramos A, Gurgui M, Borrell N, Fortún J, Moreno A, Gavalda J, Spanish Network for Research in Infectious Diseases, (2009) Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 48: 1657–1665. doi: 10.1086/599035 [CrossRef] [PubMed] [Google Scholar]
  • George IA, Santos CAQ, Olsen MA, Bailey TC, (2016) Epidemiology and Outcomes of Nontuberculous Mycobacterial Infections in Solid Organ Transplant Recipients at a Midwestern Center. Transplantation 100: 1073–1078. doi: 10.1097/TP.0000000000001123 [CrossRef] [PubMed] [Google Scholar]
  • Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K, ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America, (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367–416. doi: 10.1164/rccm.200604-571ST [CrossRef] [PubMed] [Google Scholar]
  • Lebeaux D, Freund R, van Delden C, Guillot H, Marbus SD, Matignon M, Van Wijngaerden E, Douvry B, De Greef J, Vuotto F, Tricot L, Fernández-Ruiz M, Dantal J, Hirzel C, Jais JP, Rodriguez-Nava V, Jacobs F, Lortholary O, Coussement J, European Study Group for Nocardia in Solid Organ Transplantation, European Study Group for Nocardia in Solid Organ Transplantation, (2017) Outcome and Treatment of Nocardiosis After Solid Organ Transplantation: New Insights From a European Study. Clin Infect Dis Off Publ Infect Dis Soc Am 64: 1396–1405. doi: 10.1093/cid/cix124 [CrossRef] [Google Scholar]
  • Coussement J, Lebeaux D, van Delden C, Guillot H, Freund R, Marbus S, Melica G, Van Wijngaerden E, Douvry B, Van Laecke S, Vuotto F, Tricot L, Fernández-Ruiz M, Dantal J, Hirzel C, Jais JP, Rodriguez-Nava V, Lortholary O, Jacobs F, European Study Group for Nocardia in Solid Organ Transplantation, (2016) Nocardia Infection in Solid Organ Transplant Recipients: A Multicenter European Case-control Study. Clin Infect Dis Off Publ Infect Dis Soc Am 63: 338–345. doi: 10.1093/cid/ciw241 [CrossRef] [PubMed] [Google Scholar]
  • Rúa-Figueroa Í, López-Longo J, Galindo-Izquierdo M, Calvo-Alén J, Del Campo V, Olivé-Marqués A, Pérez-Vicente S, Fernández-Nebro A, Andrés M, Erausquin C, Tomero E, Horcada L, Uriarte E, Freire M, Montilla C, Sánchez-Atrio A, Santos G, Boteanu A, Díez-Álvarez E, Narváez J, Martínez-Taboada V, Silva-Fernández L, Ruiz-Lucea E, Andreu JL, Hernández-Beriain JÁ, Gantes M, Hernández-Cruz B, Pérez-Venegas J, Pecondón-Español Á, Marras C, Ibáñez-Barceló M, Bonilla G, Torrente V, Castellví I, Alegre JJ, Calvet J, Marenco JL, Raya E, Vázquez T, Quevedo V, Muñoz-Fernández S, Rodríguez-Gómez M, Ibáñez J, Pego-Reigosa JM, (2017) Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum 47: 38–45. doi: 10.1016/j.semarthrit.2017.01.010 [CrossRef] [PubMed] [Google Scholar]
  • Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, Jayne D, Harper L, European Vasculitis Study (EUVAS) Group, (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69: 1036–1043. doi: 10.1136/ard.2009.109389 [CrossRef] [PubMed] [Google Scholar]
  • Ben m’rad M, Gherissi D, Mouthon L, Salmon-Céron D (2009) Tuberculosis risk among patients with systemic diseases. Presse Medicale Paris Fr 1983 38: 274–290. doi: 10.1016/j.lpm.2008.11.009 [CrossRef] [Google Scholar]
  • Stuck AE, Minder CE, Frey FJ, (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11: 954–963 [CrossRef] [PubMed] [Google Scholar]
  • Klein NC, Go CH, Cunha BA, (2001) Infections associated with steroid use. Infect Dis Clin North Am 15: 423–432, viii [CrossRef] [PubMed] [Google Scholar]
  • Ginzler E, Diamond H, Kaplan D, Weiner M, Schlesinger M, Seleznick M, (1978) Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 21: 37–44 [CrossRef] [PubMed] [Google Scholar]
  • Jick SS, Lieberman ES, Rahman MU, Choi HK (2006) Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55: 19–26. doi: 10.1002/art.21705 [CrossRef] [PubMed] [Google Scholar]
  • Roux A, Gonzalez F, Roux M, Mehrad M, Menotti J, Zahar JR, Tadros VX, Azoulay E, Brillet PY, Vincent F, Groupe de recherche respiratoire en réanimation en onco-hématologie (Grrr-OH), (2014) Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Med Mal Infect 44: 185–198. doi: 10.1016/j.medmal.2014.01.007 [CrossRef] [PubMed] [Google Scholar]
  • Lionakis MS, Kontoyiannis DP, (2003) Glucocorticoids and invasive fungal infections. Lancet Lond Engl 362: 1828–1838. doi: 10.1016/S0140-6736(03)14904-5 [CrossRef] [Google Scholar]
  • Segal BH, Sneller MC, (1997) Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 23: 219–237 [CrossRef] [PubMed] [Google Scholar]
  • McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L, (2009) Methotrexate, rheumatoid arthritis and infection risk: what is the evidence? Rheumatol Oxf Engl 48: 867–871. doi: 10.1093/rheumatology/kep101 [CrossRef] [Google Scholar]
  • LeMense GP, Sahn SA, (1994) Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 150: 258–260. doi: 10.1164/ajrccm.150.1.8025760 [CrossRef] [PubMed] [Google Scholar]
  • Bradley JD, Brandt KD, Katz BP, (1989) Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 32: 45–53 [CrossRef] [PubMed] [Google Scholar]
  • Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R, (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2: CD008794. doi: 10.1002/14651858.CD008794.pub2 [Google Scholar]
  • Choy EH, Panayi GS, (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907–916. doi: 10.1056/NEJM200103223441207 [CrossRef] [PubMed] [Google Scholar]
  • Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP, BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register, (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatol Oxf Engl 50: 124–131. doi: 10.1093/rheumatology/keq242 [CrossRef] [Google Scholar]
  • Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register, (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54: 2368–2376. doi: 10.1002/art.21978 [CrossRef] [PubMed] [Google Scholar]
  • Nyboe Andersen N, Pasternak B, Friis-Møller N, Andersson M, Jess T, (2015) Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 350: h2809 [CrossRef] [Google Scholar]
  • Gómez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group, (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57: 756–761. doi: 10.1002/art.22768 [CrossRef] [PubMed] [Google Scholar]
  • Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X, Research Axed on Tolerance of Biotherapies Group, (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60: 1884–1894. doi: 10.1002/art.24632 [CrossRef] [PubMed] [Google Scholar]
  • Lanternier F, Tubach F, Ravaud P, Salmon D, Dellamonica P, Bretagne S, Couret M, Bouvard B, Debandt M, Gueit I, Gendre JP, Leone J, Nicolas N, Che D, Mariette X, Lortholary O, Research Axed on Tolerance of Biotherapies Group, (2013) Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest 144: 990–998. doi: 10.1378/chest.12-2820 [CrossRef] [PubMed] [Google Scholar]
  • Wallis RS, Broder M, Wong J, Lee A, Hoq L, (2005) Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41: S194–S198. doi: 10.1086/429996 [CrossRef] [PubMed] [Google Scholar]
  • Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP, (2008) Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 83: 181–194 [CrossRef] [PubMed] [Google Scholar]
  • Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE, Club Rhumatismes et Inflammation, (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62: 2458–2466. doi: 10.1002/art.27541 [CrossRef] [PubMed] [Google Scholar]
  • Jiang X, Mei X, Feng D, Wang X, (2015) Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. PloS One 10: e0122171. doi: 10.1371/journal.pone.0122171 [CrossRef] [PubMed] [Google Scholar]
  • Kelesidis T, Daikos G, Boumpas D, Tsiodras S, (2011) Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15: e2–e16. doi: 10.1016/j.ijid.2010.03.025 [CrossRef] [PubMed] [Google Scholar]
  • van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB, (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72: 1496–1502. doi: 10.1136/annrheumdis-2012-201956 [CrossRef] [PubMed] [Google Scholar]
  • Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Bretagne S, Cordonnier C, 5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN), (2016) ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 71: 2397–2404. doi: 10.1093/jac/dkw157 [CrossRef] [PubMed] [Google Scholar]
  • Martin-Garrido I, Carmona EM, Specks U, Limper AH, (2013) Pneumocystis pneumonia in patients treated with rituximab. Chest 144: 258–265. doi: 10.1378/chest.12-0477 [CrossRef] [PubMed] [Google Scholar]
  • Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR, (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis Off Publ Infect Dis Soc Am 43: 16–24. doi: 10.1086/504811 [CrossRef] [Google Scholar]
  • Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, Shutt KA, Shapiro R, Thai N, Abu-Elmagd K, McCurry KR, Marcos A, Paterson DL, (2007) Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 44: 204–212. doi: 10.1086/510388 [CrossRef] [PubMed] [Google Scholar]
  • Sanghavi SK, Bullotta A, Husain S, Rinaldo CR, (2012) Clinical evaluation of multiplex real-time PCR panels for rapid detection of respiratory viral infections. J Med Virol 84: 162–169. doi: 10.1002/jmv.22186 [CrossRef] [PubMed] [Google Scholar]
  • Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P, (2013) Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis Off Publ Infect Dis Soc Am 56: 258–266. doi: 10.1093/cid/cis844 [CrossRef] [Google Scholar]
  • Dignan FL, Clark A, Aitken C, Gilleece M, Jayakar V, Krishnamurthy P, Pagliuca A, Potter MN, Shaw B, Skinner R, Turner A, Wynn RF, Coyle P, Haemato-oncology Task Force of the British Committee for Standards in Haematology, British Society for Blood and Marrow Transplantation and the UK Clinical Virology Network, (2016) BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. Br J Haematol 173: 380–393. doi: 10.1111/bjh.14027 [CrossRef] [PubMed] [Google Scholar]
  • Schnell D, Mayaux J, de Bazelaire C, Legoff J, Feuillet S, Scieux C, Andreu-Gallien J, Darmon M, Baruchel A, Schlemmer B, Azoulay E, (2010) Risk factors for pneumonia in immunocompromised patients with influenza. Respir Med 104: 1050–1056. doi: 10.1016/j.rmed.2010.01.021 [CrossRef] [PubMed] [Google Scholar]
  • Manuel O, López-Medrano F, Keiser L, Welte T, Carratalà J, Cordero E, Hirsch HH, ESCMID Study Group of Infection in Compromised Hosts (ESGICH), (2014) Influenza and other respiratory virus infections in solid organ transplant recipients. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 20: 102–108 [Google Scholar]
  • Cordero E, Pérez-Romero P, Moreno A, Len O, Montejo M, Vidal E, Martín-Dávila P, Fariñas MC, Fernández-Sabé N, Giannella M, Pachón J, Novel influenza A(H1N1) Study Group of Spanish Network for Research in Infectious Diseases (REIPI), (2012) Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection. Clin Microbiol Infect 18: 67–73. doi: 10.1111/j.1469-0691.2011.03537.x [CrossRef] [Google Scholar]
  • Ison MG, (2011) Antivirals and resistance: influenza virus. Curr Opin Virol 1: 563–573. doi: 10.1016/j.coviro.2011.09.002 [CrossRef] [PubMed] [Google Scholar]
  • Azoulay E, Schlemmer B, (2006) Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Med 32: 808–822. doi: 10.1007/s00134-006-0129-2 [CrossRef] [PubMed] [Google Scholar]
  • Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, Thursky KA, (2014) Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 44: 1350–1363. doi: 10.1111/imj.12599 [CrossRef] [PubMed] [Google Scholar]
  • Azoulay E, Mokart D, Lambert J, Lemiale V, Rabbat A, Kouatchet A, Vincent F, Gruson D, Bruneel F, Epinette-Branche G, Lafabrie A, Hamidfar-Roy R, Cracco C, Renard B, Tonnelier JM, Blot F, Chevret S, Schlemmer B, (2010) Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med 182: 1038–1046. doi: 10.1164/rccm.201001-0018OC [CrossRef] [PubMed] [Google Scholar]
  • Maschmeyer G, Carratalà J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M, Salwender H, Schmidt-Hieber M, Azoulay E, Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology, (2015) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 26: 21–33. doi: 10.1093/annonc/mdu192 [CrossRef] [PubMed] [Google Scholar]
  • Leroy O, Mira JP, Montravers P, Gangneux JP, Lortholary O, AmarCand Study Group, (2010) Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care Lond Engl 14: R98. doi: 10.1186/cc9033 [CrossRef] [PubMed] [Google Scholar]
  • Meije Y, Piersimoni C, Torre-Cisneros J, Dilektasli AG, Aguado JM, ESCMID Study Group of Infection in Compromised Hosts, (2014) Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect 20: 89–101. doi: 10.1111/1469-0691.12641 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.